Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.35% | 39.26% | 10.51% | -5.42% | -2.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.82% | 30.35% | -3.82% | -3.22% | 1.79% |
| Operating Income | -12.82% | -30.35% | 3.82% | 3.22% | -1.79% |
| Income Before Tax | -31.07% | -36.95% | -0.62% | -1.16% | -5.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.07% | -36.95% | -0.62% | -1.16% | -5.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.07% | -36.95% | -0.62% | -1.16% | -5.78% |
| EBIT | -12.82% | -30.35% | 3.82% | 3.22% | -1.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 12.63% | -22.38% | 4.58% | 4.48% | 2.21% |
| Normalized Basic EPS | 18.06% | -17.40% | 8.26% | 8.75% | 5.94% |
| EPS Diluted | 12.63% | -22.38% | 4.58% | 4.48% | 2.24% |
| Normalized Diluted EPS | 18.06% | -17.40% | 8.26% | 8.75% | 5.94% |
| Average Basic Shares Outstanding | 82.90% | 14.46% | 5.11% | 6.53% | 8.88% |
| Average Diluted Shares Outstanding | 82.90% | 14.46% | 5.11% | 6.53% | 8.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |